3rd Quarter - Report

THE MCMANUS GROUP for EMD SERONO, INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to IVF treatments, including the Infertility Treatment Affordability Act (H.R. 4639).

LobbyistCovered position, as disclosed
LAWREN D GEER —
JOHN MCMANUS —
ALEX WHALEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4639 (119th)

Medicare/Medicaid MMM

Support for S. 839, EPIC Act and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Policies related to the Most Favored Nation Drug Pricing Model.

LobbyistCovered position, as disclosed
LAWREN D GEER —
JOHN MCMANUS —
ALEX WHALEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1492 (119th), S. 839 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.